Senior Pharmacist, Joint Formulary & Medicines OptimisationNHS
Job summary
This is a North Central London (NCL) role, hosted by UCLH.The North Central London Medicines Optimisation Network (NCL MON) is a collaborative across NHS Provider organisations and the West and North London Integrated Care Board (WNL ICB). The NCL Joint Formulary Committee (JFC) is a principal committee within the network, which fulfils the Area Prescribing Committee function and cross-sector clinical governance for medicines.JFC is responsible for establishing whether new medicines, and new indications for existing medicines, represent a safe, equitable, evidence-based and cost-effective use of medicines. It also coordinates or facilitates the development of medicine pathways, guidelines and position statements to support medicines optimisation and reduce unwarranted variation.
Further information can be found via the WNL ICS Medicines Optimisation website: https://www.westandnorthlondon.icb.nhs.uk/our-work/medicines-optimisation/joint-formulary-committee
Main duties of the job
To provide professional support to the NCL Joint Formulary Committee and Interface Prescribing Group, as well as develop, implement and maintain a sector wide medicines formulary, shared care guidelines, medicines pathways and position statements.
Job description
For the full Person Specification and more information regarding the main responsibilities of this role, please refer to the attached Job Description.
The NCL Integrated Pharmacy & Medicines Optimisation (IPMO) Programme Team (including Joint Formulary & Medicines Optimisation pharmacists) are hosted by University College London Hospitals NHS Foundation Trust on behalf of NCL stakeholders. The offices are based at 250 Euston Road, London. Travel to other NCL sites may be required on occasion.
There is an opportunity to work remotely for part of the week.
The post is a full time maternity leave cover, on a 12 month fixed term or secondment basis.
Please note, due to anticipated high volumes of applications, this vacancy may close earlier than the listed closing date. You are advised not to delay submitting your completed application Come and be a part of the best NHS trust in England to work for, according to our staff*
- UCLH top trust to work at in England - In the most recent NHS staff survey UCLH had the highest percentage of staff who said they would recommend us as a place to work, out of all general acute or acute/community NHS trusts in England for the third year in a row.
UCLH recognises the benefits of flexible working for staff To find out more, visit: Flexible working.
To discover more about what makes UCLH a great place to work, visit: Why Choose UCLH?
About us
University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.
We provide first-class acute and specialist services across eight sites:o University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)o National Hospital for Neurology and Neurosurgeryo Royal National ENT and Eastman Dental Hospitalso University College Hospital Grafton Way Buildingo Royal London Hospital for Integrated Medicineo University College Hospital Macmillan Cancer Centreo The Hospital for Tropical Diseaseso University College Hospital at Westmoreland Street
We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.
We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.